nodes	percent_of_prediction	percent_of_DWPC	metapath
Mesalazine—PTGS2—lung cancer	0.253	1	CbGaD
Mesalazine—MPO—Cisplatin—lung cancer	0.119	0.507	CbGbCtD
Mesalazine—PTGS2—Cisplatin—lung cancer	0.041	0.175	CbGbCtD
Mesalazine—PTGS2—Etoposide—lung cancer	0.0403	0.172	CbGbCtD
Mesalazine—PTGS1—Etoposide—lung cancer	0.0341	0.145	CbGbCtD
Mesalazine—CHUK—epithelium—lung cancer	0.00303	0.0756	CbGeAlD
Mesalazine—IKBKB—respiratory system—lung cancer	0.00246	0.0615	CbGeAlD
Mesalazine—PPARG—mammary gland—lung cancer	0.0023	0.0574	CbGeAlD
Mesalazine—ALOX5—respiratory system—lung cancer	0.00204	0.051	CbGeAlD
Mesalazine—IKBKB—bronchus—lung cancer	0.00203	0.0506	CbGeAlD
Mesalazine—CHUK—lung—lung cancer	0.00193	0.0481	CbGeAlD
Mesalazine—Salicylic acid—AKR1C1—lung cancer	0.00178	0.437	CrCbGaD
Mesalazine—MPO—respiratory system—lung cancer	0.00173	0.0431	CbGeAlD
Mesalazine—ALOX5—bronchus—lung cancer	0.00168	0.042	CbGeAlD
Mesalazine—PPARG—Irinotecan—Topotecan—lung cancer	0.00166	0.33	CbGdCrCtD
Mesalazine—PPARG—respiratory system—lung cancer	0.00153	0.0383	CbGeAlD
Mesalazine—MPO—epithelium—lung cancer	0.00144	0.036	CbGeAlD
Mesalazine—PPARG—Topotecan—Irinotecan—lung cancer	0.00138	0.274	CbGdCrCtD
Mesalazine—PPARG—Etoposide—Teniposide—lung cancer	0.00137	0.272	CbGdCrCtD
Mesalazine—CHUK—lymph node—lung cancer	0.00132	0.0329	CbGeAlD
Mesalazine—IKBKB—lung—lung cancer	0.00131	0.0327	CbGeAlD
Mesalazine—PPARG—epithelium—lung cancer	0.00128	0.032	CbGeAlD
Mesalazine—ALOX5—bone marrow—lung cancer	0.0012	0.0299	CbGeAlD
Mesalazine—ALOX5—lung—lung cancer	0.00108	0.0271	CbGeAlD
Mesalazine—MPO—bone marrow—lung cancer	0.00101	0.0253	CbGeAlD
Mesalazine—MPO—lung—lung cancer	0.000918	0.0229	CbGeAlD
Mesalazine—PPARG—bone marrow—lung cancer	0.000899	0.0224	CbGeAlD
Mesalazine—IKBKB—lymph node—lung cancer	0.000895	0.0223	CbGeAlD
Mesalazine—PTGS1—respiratory system—lung cancer	0.00082	0.0205	CbGeAlD
Mesalazine—PPARG—lung—lung cancer	0.000814	0.0203	CbGeAlD
Mesalazine—PTGS2—respiratory system—lung cancer	0.000784	0.0196	CbGeAlD
Mesalazine—ALOX5—lymph node—lung cancer	0.000742	0.0185	CbGeAlD
Mesalazine—PTGS1—epithelium—lung cancer	0.000685	0.0171	CbGeAlD
Mesalazine—PTGS2—epithelium—lung cancer	0.000655	0.0163	CbGeAlD
Mesalazine—PTGS2—bronchus—lung cancer	0.000645	0.0161	CbGeAlD
Mesalazine—MPO—lymph node—lung cancer	0.000628	0.0157	CbGeAlD
Mesalazine—PPARG—Teniposide—Etoposide—lung cancer	0.000622	0.124	CbGdCrCtD
Mesalazine—PTGS1—trachea—lung cancer	0.000606	0.0151	CbGeAlD
Mesalazine—PTGS2—trachea—lung cancer	0.000579	0.0145	CbGeAlD
Mesalazine—PTGS1—cardiac atrium—lung cancer	0.000569	0.0142	CbGeAlD
Mesalazine—PPARG—lymph node—lung cancer	0.000557	0.0139	CbGeAlD
Mesalazine—Salicylate-sodium—PTGS2—lung cancer	0.000505	0.124	CrCbGaD
Mesalazine—PTGS2—bone marrow—lung cancer	0.000459	0.0115	CbGeAlD
Mesalazine—PTGS1—lung—lung cancer	0.000435	0.0109	CbGeAlD
Mesalazine—PTGS2—lung—lung cancer	0.000416	0.0104	CbGeAlD
Mesalazine—Olsalazine—PTGS2—lung cancer	0.000346	0.0851	CrCbGaD
Mesalazine—Diflunisal—PTGS2—lung cancer	0.000325	0.08	CrCbGaD
Mesalazine—Aminosalicylic Acid—PTGS2—lung cancer	0.000325	0.08	CrCbGaD
Mesalazine—PTGS1—lymph node—lung cancer	0.000298	0.00743	CbGeAlD
Mesalazine—Diflunisal—ALB—lung cancer	0.00029	0.0713	CrCbGaD
Mesalazine—PTGS2—lymph node—lung cancer	0.000285	0.0071	CbGeAlD
Mesalazine—Salicylic acid—PTGS2—lung cancer	0.000181	0.0445	CrCbGaD
Mesalazine—Salicylic acid—ALB—lung cancer	0.000161	0.0397	CrCbGaD
Mesalazine—Salicylic acid—ABCB1—lung cancer	0.000154	0.0379	CrCbGaD
Mesalazine—Confusional state—Docetaxel—lung cancer	5.41e-05	0.000199	CcSEcCtD
Mesalazine—Pharyngitis—Methotrexate—lung cancer	5.41e-05	0.000199	CcSEcCtD
Mesalazine—Urinary tract disorder—Methotrexate—lung cancer	5.38e-05	0.000198	CcSEcCtD
Mesalazine—Photosensitivity reaction—Doxorubicin—lung cancer	5.38e-05	0.000198	CcSEcCtD
Mesalazine—Anaphylactic shock—Docetaxel—lung cancer	5.37e-05	0.000197	CcSEcCtD
Mesalazine—Oedema—Docetaxel—lung cancer	5.37e-05	0.000197	CcSEcCtD
Mesalazine—Weight increased—Doxorubicin—lung cancer	5.36e-05	0.000197	CcSEcCtD
Mesalazine—Pruritus—Gemcitabine—lung cancer	5.35e-05	0.000197	CcSEcCtD
Mesalazine—Urethral disorder—Methotrexate—lung cancer	5.34e-05	0.000196	CcSEcCtD
Mesalazine—Infection—Docetaxel—lung cancer	5.33e-05	0.000196	CcSEcCtD
Mesalazine—Weight decreased—Doxorubicin—lung cancer	5.33e-05	0.000196	CcSEcCtD
Mesalazine—Feeling abnormal—Etoposide—lung cancer	5.32e-05	0.000196	CcSEcCtD
Mesalazine—Diarrhoea—Irinotecan—lung cancer	5.31e-05	0.000195	CcSEcCtD
Mesalazine—Pneumonia—Doxorubicin—lung cancer	5.28e-05	0.000194	CcSEcCtD
Mesalazine—Gastrointestinal pain—Etoposide—lung cancer	5.28e-05	0.000194	CcSEcCtD
Mesalazine—Shock—Docetaxel—lung cancer	5.28e-05	0.000194	CcSEcCtD
Mesalazine—Nervous system disorder—Docetaxel—lung cancer	5.27e-05	0.000194	CcSEcCtD
Mesalazine—Thrombocytopenia—Docetaxel—lung cancer	5.26e-05	0.000193	CcSEcCtD
Mesalazine—Infestation—Doxorubicin—lung cancer	5.25e-05	0.000193	CcSEcCtD
Mesalazine—Infestation NOS—Doxorubicin—lung cancer	5.25e-05	0.000193	CcSEcCtD
Mesalazine—Tachycardia—Docetaxel—lung cancer	5.24e-05	0.000193	CcSEcCtD
Mesalazine—Feeling abnormal—Paclitaxel—lung cancer	5.22e-05	0.000192	CcSEcCtD
Mesalazine—Skin disorder—Docetaxel—lung cancer	5.22e-05	0.000192	CcSEcCtD
Mesalazine—Stevens-Johnson syndrome—Doxorubicin—lung cancer	5.21e-05	0.000192	CcSEcCtD
Mesalazine—Hypersensitivity—Cisplatin—lung cancer	5.2e-05	0.000191	CcSEcCtD
Mesalazine—Gastrointestinal pain—Paclitaxel—lung cancer	5.18e-05	0.00019	CcSEcCtD
Mesalazine—Diarrhoea—Gemcitabine—lung cancer	5.18e-05	0.00019	CcSEcCtD
Mesalazine—Renal failure—Doxorubicin—lung cancer	5.16e-05	0.00019	CcSEcCtD
Mesalazine—Erythema multiforme—Methotrexate—lung cancer	5.15e-05	0.000189	CcSEcCtD
Mesalazine—Neuropathy peripheral—Doxorubicin—lung cancer	5.15e-05	0.000189	CcSEcCtD
Mesalazine—Dizziness—Irinotecan—lung cancer	5.14e-05	0.000189	CcSEcCtD
Mesalazine—Urticaria—Etoposide—lung cancer	5.13e-05	0.000189	CcSEcCtD
Mesalazine—Stomatitis—Doxorubicin—lung cancer	5.12e-05	0.000188	CcSEcCtD
Mesalazine—Jaundice—Doxorubicin—lung cancer	5.12e-05	0.000188	CcSEcCtD
Mesalazine—Anorexia—Docetaxel—lung cancer	5.12e-05	0.000188	CcSEcCtD
Mesalazine—Body temperature increased—Etoposide—lung cancer	5.11e-05	0.000188	CcSEcCtD
Mesalazine—Abdominal pain—Etoposide—lung cancer	5.11e-05	0.000188	CcSEcCtD
Mesalazine—Urinary tract infection—Doxorubicin—lung cancer	5.11e-05	0.000188	CcSEcCtD
Mesalazine—Conjunctivitis—Doxorubicin—lung cancer	5.11e-05	0.000188	CcSEcCtD
Mesalazine—Eye disorder—Methotrexate—lung cancer	5.09e-05	0.000187	CcSEcCtD
Mesalazine—Tinnitus—Methotrexate—lung cancer	5.08e-05	0.000187	CcSEcCtD
Mesalazine—Asthenia—Cisplatin—lung cancer	5.06e-05	0.000186	CcSEcCtD
Mesalazine—Cardiac disorder—Methotrexate—lung cancer	5.06e-05	0.000186	CcSEcCtD
Mesalazine—Sweating—Doxorubicin—lung cancer	5.04e-05	0.000185	CcSEcCtD
Mesalazine—Urticaria—Paclitaxel—lung cancer	5.03e-05	0.000185	CcSEcCtD
Mesalazine—Hypotension—Docetaxel—lung cancer	5.02e-05	0.000184	CcSEcCtD
Mesalazine—Haematuria—Doxorubicin—lung cancer	5.01e-05	0.000184	CcSEcCtD
Mesalazine—Body temperature increased—Paclitaxel—lung cancer	5.01e-05	0.000184	CcSEcCtD
Mesalazine—Abdominal pain—Paclitaxel—lung cancer	5.01e-05	0.000184	CcSEcCtD
Mesalazine—Hepatobiliary disease—Doxorubicin—lung cancer	4.97e-05	0.000183	CcSEcCtD
Mesalazine—Epistaxis—Doxorubicin—lung cancer	4.96e-05	0.000182	CcSEcCtD
Mesalazine—Angiopathy—Methotrexate—lung cancer	4.94e-05	0.000182	CcSEcCtD
Mesalazine—Vomiting—Irinotecan—lung cancer	4.94e-05	0.000182	CcSEcCtD
Mesalazine—Sinusitis—Doxorubicin—lung cancer	4.93e-05	0.000181	CcSEcCtD
Mesalazine—Immune system disorder—Methotrexate—lung cancer	4.92e-05	0.000181	CcSEcCtD
Mesalazine—Mediastinal disorder—Methotrexate—lung cancer	4.91e-05	0.000181	CcSEcCtD
Mesalazine—Agranulocytosis—Doxorubicin—lung cancer	4.9e-05	0.00018	CcSEcCtD
Mesalazine—Rash—Irinotecan—lung cancer	4.9e-05	0.00018	CcSEcCtD
Mesalazine—Dermatitis—Irinotecan—lung cancer	4.89e-05	0.00018	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Docetaxel—lung cancer	4.89e-05	0.00018	CcSEcCtD
Mesalazine—Chills—Methotrexate—lung cancer	4.89e-05	0.00018	CcSEcCtD
Mesalazine—Headache—Irinotecan—lung cancer	4.87e-05	0.000179	CcSEcCtD
Mesalazine—Insomnia—Docetaxel—lung cancer	4.86e-05	0.000179	CcSEcCtD
Mesalazine—Diarrhoea—Cisplatin—lung cancer	4.83e-05	0.000177	CcSEcCtD
Mesalazine—Paraesthesia—Docetaxel—lung cancer	4.82e-05	0.000177	CcSEcCtD
Mesalazine—Alopecia—Methotrexate—lung cancer	4.81e-05	0.000177	CcSEcCtD
Mesalazine—Vomiting—Gemcitabine—lung cancer	4.81e-05	0.000177	CcSEcCtD
Mesalazine—Dyspnoea—Docetaxel—lung cancer	4.79e-05	0.000176	CcSEcCtD
Mesalazine—Somnolence—Docetaxel—lung cancer	4.77e-05	0.000176	CcSEcCtD
Mesalazine—Mental disorder—Methotrexate—lung cancer	4.77e-05	0.000175	CcSEcCtD
Mesalazine—Rash—Gemcitabine—lung cancer	4.77e-05	0.000175	CcSEcCtD
Mesalazine—Dermatitis—Gemcitabine—lung cancer	4.77e-05	0.000175	CcSEcCtD
Mesalazine—Hypersensitivity—Etoposide—lung cancer	4.76e-05	0.000175	CcSEcCtD
Mesalazine—Erythema—Methotrexate—lung cancer	4.74e-05	0.000174	CcSEcCtD
Mesalazine—Haemoglobin—Doxorubicin—lung cancer	4.74e-05	0.000174	CcSEcCtD
Mesalazine—Headache—Gemcitabine—lung cancer	4.74e-05	0.000174	CcSEcCtD
Mesalazine—Rhinitis—Doxorubicin—lung cancer	4.73e-05	0.000174	CcSEcCtD
Mesalazine—Dyspepsia—Docetaxel—lung cancer	4.73e-05	0.000174	CcSEcCtD
Mesalazine—Hepatitis—Doxorubicin—lung cancer	4.72e-05	0.000173	CcSEcCtD
Mesalazine—Haemorrhage—Doxorubicin—lung cancer	4.72e-05	0.000173	CcSEcCtD
Mesalazine—Pharyngitis—Doxorubicin—lung cancer	4.68e-05	0.000172	CcSEcCtD
Mesalazine—Decreased appetite—Docetaxel—lung cancer	4.67e-05	0.000172	CcSEcCtD
Mesalazine—Hypersensitivity—Paclitaxel—lung cancer	4.67e-05	0.000172	CcSEcCtD
Mesalazine—Urinary tract disorder—Doxorubicin—lung cancer	4.66e-05	0.000171	CcSEcCtD
Mesalazine—Oedema peripheral—Doxorubicin—lung cancer	4.65e-05	0.000171	CcSEcCtD
Mesalazine—Dysgeusia—Methotrexate—lung cancer	4.64e-05	0.000171	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Docetaxel—lung cancer	4.64e-05	0.00017	CcSEcCtD
Mesalazine—Asthenia—Etoposide—lung cancer	4.64e-05	0.00017	CcSEcCtD
Mesalazine—Connective tissue disorder—Doxorubicin—lung cancer	4.63e-05	0.00017	CcSEcCtD
Mesalazine—Fatigue—Docetaxel—lung cancer	4.63e-05	0.00017	CcSEcCtD
Mesalazine—Urethral disorder—Doxorubicin—lung cancer	4.62e-05	0.00017	CcSEcCtD
Mesalazine—Nausea—Irinotecan—lung cancer	4.61e-05	0.00017	CcSEcCtD
Mesalazine—Pain—Docetaxel—lung cancer	4.59e-05	0.000169	CcSEcCtD
Mesalazine—Constipation—Docetaxel—lung cancer	4.59e-05	0.000169	CcSEcCtD
Mesalazine—Back pain—Methotrexate—lung cancer	4.59e-05	0.000169	CcSEcCtD
Mesalazine—Pruritus—Etoposide—lung cancer	4.57e-05	0.000168	CcSEcCtD
Mesalazine—Asthenia—Paclitaxel—lung cancer	4.54e-05	0.000167	CcSEcCtD
Mesalazine—Nausea—Gemcitabine—lung cancer	4.49e-05	0.000165	CcSEcCtD
Mesalazine—Vomiting—Cisplatin—lung cancer	4.48e-05	0.000165	CcSEcCtD
Mesalazine—Pruritus—Paclitaxel—lung cancer	4.48e-05	0.000165	CcSEcCtD
Mesalazine—Vision blurred—Methotrexate—lung cancer	4.47e-05	0.000164	CcSEcCtD
Mesalazine—Erythema multiforme—Doxorubicin—lung cancer	4.46e-05	0.000164	CcSEcCtD
Mesalazine—Rash—Cisplatin—lung cancer	4.45e-05	0.000163	CcSEcCtD
Mesalazine—Dermatitis—Cisplatin—lung cancer	4.44e-05	0.000163	CcSEcCtD
Mesalazine—Feeling abnormal—Docetaxel—lung cancer	4.42e-05	0.000163	CcSEcCtD
Mesalazine—Diarrhoea—Etoposide—lung cancer	4.42e-05	0.000163	CcSEcCtD
Mesalazine—Eye disorder—Doxorubicin—lung cancer	4.41e-05	0.000162	CcSEcCtD
Mesalazine—Ill-defined disorder—Methotrexate—lung cancer	4.4e-05	0.000162	CcSEcCtD
Mesalazine—Tinnitus—Doxorubicin—lung cancer	4.4e-05	0.000162	CcSEcCtD
Mesalazine—Gastrointestinal pain—Docetaxel—lung cancer	4.39e-05	0.000161	CcSEcCtD
Mesalazine—Anaemia—Methotrexate—lung cancer	4.38e-05	0.000161	CcSEcCtD
Mesalazine—Cardiac disorder—Doxorubicin—lung cancer	4.38e-05	0.000161	CcSEcCtD
Mesalazine—Diarrhoea—Paclitaxel—lung cancer	4.33e-05	0.000159	CcSEcCtD
Mesalazine—Angiopathy—Doxorubicin—lung cancer	4.28e-05	0.000157	CcSEcCtD
Mesalazine—Malaise—Methotrexate—lung cancer	4.28e-05	0.000157	CcSEcCtD
Mesalazine—Dizziness—Etoposide—lung cancer	4.27e-05	0.000157	CcSEcCtD
Mesalazine—Immune system disorder—Doxorubicin—lung cancer	4.26e-05	0.000157	CcSEcCtD
Mesalazine—Vertigo—Methotrexate—lung cancer	4.26e-05	0.000157	CcSEcCtD
Mesalazine—Mediastinal disorder—Doxorubicin—lung cancer	4.25e-05	0.000156	CcSEcCtD
Mesalazine—Body temperature increased—Docetaxel—lung cancer	4.24e-05	0.000156	CcSEcCtD
Mesalazine—Abdominal pain—Docetaxel—lung cancer	4.24e-05	0.000156	CcSEcCtD
Mesalazine—Leukopenia—Methotrexate—lung cancer	4.24e-05	0.000156	CcSEcCtD
Mesalazine—Chills—Doxorubicin—lung cancer	4.23e-05	0.000156	CcSEcCtD
Mesalazine—Dizziness—Paclitaxel—lung cancer	4.19e-05	0.000154	CcSEcCtD
Mesalazine—Nausea—Cisplatin—lung cancer	4.19e-05	0.000154	CcSEcCtD
Mesalazine—Alopecia—Doxorubicin—lung cancer	4.17e-05	0.000153	CcSEcCtD
Mesalazine—Cough—Methotrexate—lung cancer	4.14e-05	0.000152	CcSEcCtD
Mesalazine—Mental disorder—Doxorubicin—lung cancer	4.13e-05	0.000152	CcSEcCtD
Mesalazine—Vomiting—Etoposide—lung cancer	4.11e-05	0.000151	CcSEcCtD
Mesalazine—Erythema—Doxorubicin—lung cancer	4.11e-05	0.000151	CcSEcCtD
Mesalazine—Rash—Etoposide—lung cancer	4.07e-05	0.00015	CcSEcCtD
Mesalazine—Dermatitis—Etoposide—lung cancer	4.07e-05	0.00015	CcSEcCtD
Mesalazine—Headache—Etoposide—lung cancer	4.05e-05	0.000149	CcSEcCtD
Mesalazine—Flatulence—Doxorubicin—lung cancer	4.05e-05	0.000149	CcSEcCtD
Mesalazine—Myalgia—Methotrexate—lung cancer	4.04e-05	0.000148	CcSEcCtD
Mesalazine—Arthralgia—Methotrexate—lung cancer	4.04e-05	0.000148	CcSEcCtD
Mesalazine—Chest pain—Methotrexate—lung cancer	4.04e-05	0.000148	CcSEcCtD
Mesalazine—Tension—Doxorubicin—lung cancer	4.03e-05	0.000148	CcSEcCtD
Mesalazine—Vomiting—Paclitaxel—lung cancer	4.03e-05	0.000148	CcSEcCtD
Mesalazine—Dysgeusia—Doxorubicin—lung cancer	4.02e-05	0.000148	CcSEcCtD
Mesalazine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	4.01e-05	0.000147	CcSEcCtD
Mesalazine—Rash—Paclitaxel—lung cancer	3.99e-05	0.000147	CcSEcCtD
Mesalazine—Dermatitis—Paclitaxel—lung cancer	3.99e-05	0.000147	CcSEcCtD
Mesalazine—Discomfort—Methotrexate—lung cancer	3.99e-05	0.000147	CcSEcCtD
Mesalazine—Nervousness—Doxorubicin—lung cancer	3.99e-05	0.000147	CcSEcCtD
Mesalazine—Back pain—Doxorubicin—lung cancer	3.97e-05	0.000146	CcSEcCtD
Mesalazine—Headache—Paclitaxel—lung cancer	3.97e-05	0.000146	CcSEcCtD
Mesalazine—Hypersensitivity—Docetaxel—lung cancer	3.96e-05	0.000145	CcSEcCtD
Mesalazine—Muscle spasms—Doxorubicin—lung cancer	3.95e-05	0.000145	CcSEcCtD
Mesalazine—Confusional state—Methotrexate—lung cancer	3.9e-05	0.000143	CcSEcCtD
Mesalazine—Anaphylactic shock—Methotrexate—lung cancer	3.87e-05	0.000142	CcSEcCtD
Mesalazine—Vision blurred—Doxorubicin—lung cancer	3.87e-05	0.000142	CcSEcCtD
Mesalazine—Asthenia—Docetaxel—lung cancer	3.85e-05	0.000142	CcSEcCtD
Mesalazine—Infection—Methotrexate—lung cancer	3.84e-05	0.000141	CcSEcCtD
Mesalazine—Nausea—Etoposide—lung cancer	3.84e-05	0.000141	CcSEcCtD
Mesalazine—Ill-defined disorder—Doxorubicin—lung cancer	3.81e-05	0.00014	CcSEcCtD
Mesalazine—Pruritus—Docetaxel—lung cancer	3.8e-05	0.00014	CcSEcCtD
Mesalazine—Nervous system disorder—Methotrexate—lung cancer	3.8e-05	0.00014	CcSEcCtD
Mesalazine—Anaemia—Doxorubicin—lung cancer	3.79e-05	0.00014	CcSEcCtD
Mesalazine—Thrombocytopenia—Methotrexate—lung cancer	3.79e-05	0.000139	CcSEcCtD
Mesalazine—Nausea—Paclitaxel—lung cancer	3.76e-05	0.000138	CcSEcCtD
Mesalazine—Skin disorder—Methotrexate—lung cancer	3.76e-05	0.000138	CcSEcCtD
Mesalazine—Hyperhidrosis—Methotrexate—lung cancer	3.74e-05	0.000138	CcSEcCtD
Mesalazine—Malaise—Doxorubicin—lung cancer	3.7e-05	0.000136	CcSEcCtD
Mesalazine—Vertigo—Doxorubicin—lung cancer	3.69e-05	0.000136	CcSEcCtD
Mesalazine—Anorexia—Methotrexate—lung cancer	3.69e-05	0.000136	CcSEcCtD
Mesalazine—Syncope—Doxorubicin—lung cancer	3.68e-05	0.000135	CcSEcCtD
Mesalazine—Leukopenia—Doxorubicin—lung cancer	3.68e-05	0.000135	CcSEcCtD
Mesalazine—Diarrhoea—Docetaxel—lung cancer	3.67e-05	0.000135	CcSEcCtD
Mesalazine—Palpitations—Doxorubicin—lung cancer	3.63e-05	0.000133	CcSEcCtD
Mesalazine—Hypotension—Methotrexate—lung cancer	3.62e-05	0.000133	CcSEcCtD
Mesalazine—Loss of consciousness—Doxorubicin—lung cancer	3.61e-05	0.000133	CcSEcCtD
Mesalazine—Cough—Doxorubicin—lung cancer	3.58e-05	0.000132	CcSEcCtD
Mesalazine—Dizziness—Docetaxel—lung cancer	3.55e-05	0.000131	CcSEcCtD
Mesalazine—Hypertension—Doxorubicin—lung cancer	3.54e-05	0.00013	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Methotrexate—lung cancer	3.53e-05	0.00013	CcSEcCtD
Mesalazine—Insomnia—Methotrexate—lung cancer	3.5e-05	0.000129	CcSEcCtD
Mesalazine—Myalgia—Doxorubicin—lung cancer	3.5e-05	0.000129	CcSEcCtD
Mesalazine—Arthralgia—Doxorubicin—lung cancer	3.5e-05	0.000129	CcSEcCtD
Mesalazine—Chest pain—Doxorubicin—lung cancer	3.5e-05	0.000129	CcSEcCtD
Mesalazine—Anxiety—Doxorubicin—lung cancer	3.48e-05	0.000128	CcSEcCtD
Mesalazine—Paraesthesia—Methotrexate—lung cancer	3.47e-05	0.000128	CcSEcCtD
Mesalazine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	3.47e-05	0.000128	CcSEcCtD
Mesalazine—Discomfort—Doxorubicin—lung cancer	3.45e-05	0.000127	CcSEcCtD
Mesalazine—Dyspnoea—Methotrexate—lung cancer	3.45e-05	0.000127	CcSEcCtD
Mesalazine—Somnolence—Methotrexate—lung cancer	3.44e-05	0.000126	CcSEcCtD
Mesalazine—Dry mouth—Doxorubicin—lung cancer	3.42e-05	0.000126	CcSEcCtD
Mesalazine—Vomiting—Docetaxel—lung cancer	3.41e-05	0.000126	CcSEcCtD
Mesalazine—Dyspepsia—Methotrexate—lung cancer	3.41e-05	0.000125	CcSEcCtD
Mesalazine—Rash—Docetaxel—lung cancer	3.39e-05	0.000124	CcSEcCtD
Mesalazine—Dermatitis—Docetaxel—lung cancer	3.38e-05	0.000124	CcSEcCtD
Mesalazine—Confusional state—Doxorubicin—lung cancer	3.38e-05	0.000124	CcSEcCtD
Mesalazine—Decreased appetite—Methotrexate—lung cancer	3.36e-05	0.000124	CcSEcCtD
Mesalazine—Headache—Docetaxel—lung cancer	3.36e-05	0.000124	CcSEcCtD
Mesalazine—Anaphylactic shock—Doxorubicin—lung cancer	3.35e-05	0.000123	CcSEcCtD
Mesalazine—Oedema—Doxorubicin—lung cancer	3.35e-05	0.000123	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Methotrexate—lung cancer	3.34e-05	0.000123	CcSEcCtD
Mesalazine—Fatigue—Methotrexate—lung cancer	3.34e-05	0.000123	CcSEcCtD
Mesalazine—Infection—Doxorubicin—lung cancer	3.33e-05	0.000122	CcSEcCtD
Mesalazine—Pain—Methotrexate—lung cancer	3.31e-05	0.000122	CcSEcCtD
Mesalazine—Shock—Doxorubicin—lung cancer	3.3e-05	0.000121	CcSEcCtD
Mesalazine—Nervous system disorder—Doxorubicin—lung cancer	3.29e-05	0.000121	CcSEcCtD
Mesalazine—Thrombocytopenia—Doxorubicin—lung cancer	3.28e-05	0.000121	CcSEcCtD
Mesalazine—Tachycardia—Doxorubicin—lung cancer	3.27e-05	0.00012	CcSEcCtD
Mesalazine—Skin disorder—Doxorubicin—lung cancer	3.25e-05	0.00012	CcSEcCtD
Mesalazine—Hyperhidrosis—Doxorubicin—lung cancer	3.24e-05	0.000119	CcSEcCtD
Mesalazine—Anorexia—Doxorubicin—lung cancer	3.19e-05	0.000117	CcSEcCtD
Mesalazine—Nausea—Docetaxel—lung cancer	3.19e-05	0.000117	CcSEcCtD
Mesalazine—Feeling abnormal—Methotrexate—lung cancer	3.19e-05	0.000117	CcSEcCtD
Mesalazine—Gastrointestinal pain—Methotrexate—lung cancer	3.16e-05	0.000116	CcSEcCtD
Mesalazine—Hypotension—Doxorubicin—lung cancer	3.13e-05	0.000115	CcSEcCtD
Mesalazine—Urticaria—Methotrexate—lung cancer	3.07e-05	0.000113	CcSEcCtD
Mesalazine—Abdominal pain—Methotrexate—lung cancer	3.06e-05	0.000112	CcSEcCtD
Mesalazine—Body temperature increased—Methotrexate—lung cancer	3.06e-05	0.000112	CcSEcCtD
Mesalazine—Musculoskeletal discomfort—Doxorubicin—lung cancer	3.05e-05	0.000112	CcSEcCtD
Mesalazine—Insomnia—Doxorubicin—lung cancer	3.03e-05	0.000111	CcSEcCtD
Mesalazine—Paraesthesia—Doxorubicin—lung cancer	3.01e-05	0.000111	CcSEcCtD
Mesalazine—Dyspnoea—Doxorubicin—lung cancer	2.99e-05	0.00011	CcSEcCtD
Mesalazine—Somnolence—Doxorubicin—lung cancer	2.98e-05	0.00011	CcSEcCtD
Mesalazine—Dyspepsia—Doxorubicin—lung cancer	2.95e-05	0.000108	CcSEcCtD
Mesalazine—Decreased appetite—Doxorubicin—lung cancer	2.91e-05	0.000107	CcSEcCtD
Mesalazine—Gastrointestinal disorder—Doxorubicin—lung cancer	2.89e-05	0.000106	CcSEcCtD
Mesalazine—Fatigue—Doxorubicin—lung cancer	2.89e-05	0.000106	CcSEcCtD
Mesalazine—Pain—Doxorubicin—lung cancer	2.87e-05	0.000105	CcSEcCtD
Mesalazine—Constipation—Doxorubicin—lung cancer	2.87e-05	0.000105	CcSEcCtD
Mesalazine—Hypersensitivity—Methotrexate—lung cancer	2.85e-05	0.000105	CcSEcCtD
Mesalazine—Asthenia—Methotrexate—lung cancer	2.78e-05	0.000102	CcSEcCtD
Mesalazine—Feeling abnormal—Doxorubicin—lung cancer	2.76e-05	0.000102	CcSEcCtD
Mesalazine—Gastrointestinal pain—Doxorubicin—lung cancer	2.74e-05	0.000101	CcSEcCtD
Mesalazine—Pruritus—Methotrexate—lung cancer	2.74e-05	0.000101	CcSEcCtD
Mesalazine—Urticaria—Doxorubicin—lung cancer	2.66e-05	9.79e-05	CcSEcCtD
Mesalazine—Abdominal pain—Doxorubicin—lung cancer	2.65e-05	9.74e-05	CcSEcCtD
Mesalazine—Body temperature increased—Doxorubicin—lung cancer	2.65e-05	9.74e-05	CcSEcCtD
Mesalazine—Diarrhoea—Methotrexate—lung cancer	2.65e-05	9.74e-05	CcSEcCtD
Mesalazine—Dizziness—Methotrexate—lung cancer	2.56e-05	9.41e-05	CcSEcCtD
Mesalazine—Hypersensitivity—Doxorubicin—lung cancer	2.47e-05	9.08e-05	CcSEcCtD
Mesalazine—Vomiting—Methotrexate—lung cancer	2.46e-05	9.05e-05	CcSEcCtD
Mesalazine—Rash—Methotrexate—lung cancer	2.44e-05	8.97e-05	CcSEcCtD
Mesalazine—Dermatitis—Methotrexate—lung cancer	2.44e-05	8.96e-05	CcSEcCtD
Mesalazine—Headache—Methotrexate—lung cancer	2.42e-05	8.91e-05	CcSEcCtD
Mesalazine—Asthenia—Doxorubicin—lung cancer	2.4e-05	8.84e-05	CcSEcCtD
Mesalazine—Pruritus—Doxorubicin—lung cancer	2.37e-05	8.72e-05	CcSEcCtD
Mesalazine—Nausea—Methotrexate—lung cancer	2.3e-05	8.45e-05	CcSEcCtD
Mesalazine—Diarrhoea—Doxorubicin—lung cancer	2.29e-05	8.43e-05	CcSEcCtD
Mesalazine—Dizziness—Doxorubicin—lung cancer	2.22e-05	8.15e-05	CcSEcCtD
Mesalazine—Vomiting—Doxorubicin—lung cancer	2.13e-05	7.83e-05	CcSEcCtD
Mesalazine—Rash—Doxorubicin—lung cancer	2.11e-05	7.77e-05	CcSEcCtD
Mesalazine—Dermatitis—Doxorubicin—lung cancer	2.11e-05	7.76e-05	CcSEcCtD
Mesalazine—Headache—Doxorubicin—lung cancer	2.1e-05	7.72e-05	CcSEcCtD
Mesalazine—Nausea—Doxorubicin—lung cancer	1.99e-05	7.32e-05	CcSEcCtD
Mesalazine—PTGS1—Metabolism—TYMS—lung cancer	9.18e-06	4.8e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—RAF1—lung cancer	9.17e-06	4.79e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—POMC—lung cancer	9.16e-06	4.79e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—GSTM1—lung cancer	9.08e-06	4.74e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—ERBB2—lung cancer	9.07e-06	4.74e-05	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—PIK3CA—lung cancer	9e-06	4.7e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—TERT—lung cancer	8.96e-06	4.69e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—MTOR—lung cancer	8.95e-06	4.68e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—PIK3CB—lung cancer	8.95e-06	4.68e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—CD4—lung cancer	8.93e-06	4.67e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—CREBBP—lung cancer	8.92e-06	4.66e-05	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—KRAS—lung cancer	8.88e-06	4.64e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—FGFR1—lung cancer	8.7e-06	4.55e-05	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—HRAS—lung cancer	8.67e-06	4.53e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—HES1—lung cancer	8.65e-06	4.52e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—CYP1A1—lung cancer	8.6e-06	4.5e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—HIF1A—lung cancer	8.57e-06	4.48e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—ERCC2—lung cancer	8.53e-06	4.46e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—PIK3CA—lung cancer	8.49e-06	4.44e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—MDM2—lung cancer	8.49e-06	4.44e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—ERBB3—lung cancer	8.48e-06	4.43e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—STK11—lung cancer	8.47e-06	4.43e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—RAF1—lung cancer	8.46e-06	4.42e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PIK3CD—lung cancer	8.46e-06	4.42e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—ERBB2—lung cancer	8.37e-06	4.38e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—ALB—lung cancer	8.35e-06	4.36e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—MDM2—lung cancer	8.34e-06	4.36e-05	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—HRAS—lung cancer	8.32e-06	4.35e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—RAF1—lung cancer	8.31e-06	4.35e-05	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—IL6—lung cancer	8.3e-06	4.34e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—APOA1—lung cancer	8.27e-06	4.32e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—MTOR—lung cancer	8.26e-06	4.32e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—PIK3CB—lung cancer	8.26e-06	4.32e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—CD4—lung cancer	8.25e-06	4.31e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—ERBB2—lung cancer	8.22e-06	4.3e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—IL2—lung cancer	8.22e-06	4.3e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—KDR—lung cancer	8.2e-06	4.29e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—PTGS2—lung cancer	8.19e-06	4.28e-05	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—PIK3CA—lung cancer	8.16e-06	4.26e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—TERT—lung cancer	8.13e-06	4.25e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—PIK3CB—lung cancer	8.12e-06	4.24e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—MTOR—lung cancer	8.12e-06	4.24e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CD4—lung cancer	8.1e-06	4.23e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—ERCC2—lung cancer	8.09e-06	4.23e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—JUN—lung cancer	8e-06	4.18e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—PTEN—lung cancer	7.95e-06	4.16e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—ERBB3—lung cancer	7.91e-06	4.14e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—FGFR1—lung cancer	7.89e-06	4.13e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—HRAS—lung cancer	7.86e-06	4.11e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—GSTP1—lung cancer	7.84e-06	4.1e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—HIF1A—lung cancer	7.77e-06	4.06e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—CDKN1A—lung cancer	7.75e-06	4.05e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—PTEN—lung cancer	7.73e-06	4.04e-05	CbGpPWpGaD
Mesalazine—CHUK—Innate Immune System—AKT1—lung cancer	7.65e-06	4e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—CAT—lung cancer	7.63e-06	3.99e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—EP300—lung cancer	7.59e-06	3.97e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—TERT—lung cancer	7.58e-06	3.96e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—APC—lung cancer	7.55e-06	3.95e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—KIT—lung cancer	7.55e-06	3.95e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PIK3CG—lung cancer	7.55e-06	3.95e-05	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—HRAS—lung cancer	7.55e-06	3.94e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—IL6—lung cancer	7.52e-06	3.93e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—APOA1—lung cancer	7.5e-06	3.92e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—EGF—lung cancer	7.46e-06	3.9e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—IL2—lung cancer	7.45e-06	3.9e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—KDR—lung cancer	7.43e-06	3.89e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—ABCB1—lung cancer	7.42e-06	3.88e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—APOA1—lung cancer	7.38e-06	3.86e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—EP300—lung cancer	7.38e-06	3.86e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PIK3CB—lung cancer	7.37e-06	3.85e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—FGFR1—lung cancer	7.36e-06	3.85e-05	CbGpPWpGaD
Mesalazine—CHUK—Adaptive Immune System—AKT1—lung cancer	7.35e-06	3.84e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PTGS2—lung cancer	7.3e-06	3.82e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—TYMS—lung cancer	7.29e-06	3.81e-05	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—PIK3CA—lung cancer	7.26e-06	3.79e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—HIF1A—lung cancer	7.25e-06	3.79e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—JUN—lung cancer	7.25e-06	3.79e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—GSTM1—lung cancer	7.2e-06	3.77e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—POMC—lung cancer	7.19e-06	3.76e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—SRC—lung cancer	7.17e-06	3.75e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—CDKN1A—lung cancer	7.16e-06	3.74e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—PTEN—lung cancer	7.14e-06	3.73e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—BRAF—lung cancer	7.1e-06	3.71e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	7.07e-06	3.69e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—CDKN1A—lung cancer	7.03e-06	3.67e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—PTEN—lung cancer	7.01e-06	3.67e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—IL6R—lung cancer	7.01e-06	3.67e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CREBBP—lung cancer	7e-06	3.66e-05	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—MAPK3—lung cancer	7e-06	3.66e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—APOA1—lung cancer	7e-06	3.66e-05	CbGpPWpGaD
Mesalazine—IKBKB—Innate Immune System—AKT1—lung cancer	6.94e-06	3.63e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—STAT3—lung cancer	6.92e-06	3.62e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—NRAS—lung cancer	6.9e-06	3.61e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—KIT—lung cancer	6.85e-06	3.58e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PIK3CG—lung cancer	6.85e-06	3.58e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—APC—lung cancer	6.85e-06	3.58e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—CYP1A1—lung cancer	6.83e-06	3.57e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—EP300—lung cancer	6.81e-06	3.56e-05	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—MYC—lung cancer	6.81e-06	3.56e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—ERCC2—lung cancer	6.77e-06	3.54e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—EGF—lung cancer	6.77e-06	3.54e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PIK3CG—lung cancer	6.74e-06	3.52e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—EP300—lung cancer	6.69e-06	3.5e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MAP2K1—lung cancer	6.68e-06	3.49e-05	CbGpPWpGaD
Mesalazine—IKBKB—Adaptive Immune System—AKT1—lung cancer	6.66e-06	3.48e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PIK3CD—lung cancer	6.64e-06	3.47e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—SRC—lung cancer	6.62e-06	3.46e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—MAPK3—lung cancer	6.61e-06	3.45e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—POMC—lung cancer	6.52e-06	3.41e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—SRC—lung cancer	6.5e-06	3.4e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—BRAF—lung cancer	6.44e-06	3.36e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—POMC—lung cancer	6.41e-06	3.35e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—KIT—lung cancer	6.39e-06	3.34e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—APC—lung cancer	6.39e-06	3.34e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—STAT3—lung cancer	6.39e-06	3.34e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—NRAS—lung cancer	6.37e-06	3.33e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PTEN—lung cancer	6.37e-06	3.33e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—IL6R—lung cancer	6.36e-06	3.32e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CREBBP—lung cancer	6.35e-06	3.32e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—EGF—lung cancer	6.31e-06	3.3e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—EGFR—lung cancer	6.29e-06	3.29e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—STAT3—lung cancer	6.27e-06	3.28e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—NRAS—lung cancer	6.26e-06	3.27e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—CREBBP—lung cancer	6.25e-06	3.27e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—MAPK3—lung cancer	6.1e-06	3.19e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—EP300—lung cancer	6.07e-06	3.18e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MAP2K1—lung cancer	6.06e-06	3.17e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PIK3CD—lung cancer	6.02e-06	3.15e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—BRAF—lung cancer	6e-06	3.14e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—MAPK3—lung cancer	5.99e-06	3.13e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MDM2—lung cancer	5.95e-06	3.11e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—KRAS—lung cancer	5.94e-06	3.1e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—MYC—lung cancer	5.93e-06	3.1e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—IL6R—lung cancer	5.93e-06	3.1e-05	CbGpPWpGaD
Mesalazine—ALOX5—Metabolism—AKT1—lung cancer	5.93e-06	3.1e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—RAF1—lung cancer	5.93e-06	3.1e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PIK3CD—lung cancer	5.92e-06	3.1e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—CREBBP—lung cancer	5.92e-06	3.1e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—ERBB2—lung cancer	5.86e-06	3.07e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—APOA1—lung cancer	5.86e-06	3.06e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—ALB—lung cancer	5.85e-06	3.06e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—EGFR—lung cancer	5.8e-06	3.03e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MTOR—lung cancer	5.79e-06	3.02e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PIK3CB—lung cancer	5.79e-06	3.02e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—EGFR—lung cancer	5.7e-06	2.98e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—MAP2K1—lung cancer	5.65e-06	2.95e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PIK3CD—lung cancer	5.62e-06	2.94e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—lung cancer	5.61e-06	2.93e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CXCL8—lung cancer	5.56e-06	2.91e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—KRAS—lung cancer	5.48e-06	2.87e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—PIK3CA—lung cancer	5.46e-06	2.85e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MDM2—lung cancer	5.39e-06	2.82e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—KRAS—lung cancer	5.39e-06	2.81e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—RAF1—lung cancer	5.37e-06	2.81e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PIK3CG—lung cancer	5.35e-06	2.8e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CASP3—lung cancer	5.32e-06	2.78e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—ERBB2—lung cancer	5.32e-06	2.78e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—IL2—lung cancer	5.31e-06	2.78e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PIK3CB—lung cancer	5.25e-06	2.74e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MTOR—lung cancer	5.25e-06	2.74e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CCND1—lung cancer	5.18e-06	2.71e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—JUN—lung cancer	5.17e-06	2.7e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PIK3CB—lung cancer	5.16e-06	2.7e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PTGS2—lung cancer	5.12e-06	2.67e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—POMC—lung cancer	5.09e-06	2.66e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—HRAS—lung cancer	5.05e-06	2.64e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CXCL8—lung cancer	5.04e-06	2.64e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—PIK3CA—lung cancer	5.04e-06	2.63e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—MDM2—lung cancer	5.03e-06	2.63e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MMP9—lung cancer	5.03e-06	2.63e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—RAF1—lung cancer	5.01e-06	2.62e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—CDKN1A—lung cancer	5.01e-06	2.62e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PTEN—lung cancer	5e-06	2.61e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—CREBBP—lung cancer	4.96e-06	2.59e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—ERBB2—lung cancer	4.96e-06	2.59e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—PIK3CA—lung cancer	4.95e-06	2.59e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PIK3CB—lung cancer	4.89e-06	2.56e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—MTOR—lung cancer	4.89e-06	2.56e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—CD4—lung cancer	4.89e-06	2.55e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—IL6—lung cancer	4.83e-06	2.53e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CASP3—lung cancer	4.83e-06	2.52e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—IL2—lung cancer	4.82e-06	2.52e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—EP300—lung cancer	4.77e-06	2.49e-05	CbGpPWpGaD
Mesalazine—PPARG—Gene Expression—AKT1—lung cancer	4.72e-06	2.47e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PIK3CD—lung cancer	4.7e-06	2.46e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CCND1—lung cancer	4.7e-06	2.46e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—JUN—lung cancer	4.69e-06	2.45e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—HRAS—lung cancer	4.66e-06	2.44e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—ALB—lung cancer	4.64e-06	2.43e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—SRC—lung cancer	4.64e-06	2.42e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—HRAS—lung cancer	4.58e-06	2.39e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MMP9—lung cancer	4.56e-06	2.38e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—CDKN1A—lung cancer	4.54e-06	2.38e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PTEN—lung cancer	4.53e-06	2.37e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—VEGFA—lung cancer	4.52e-06	2.36e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—PIK3CA—lung cancer	4.49e-06	2.35e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—STAT3—lung cancer	4.47e-06	2.34e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PTEN—lung cancer	4.46e-06	2.33e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—NRAS—lung cancer	4.46e-06	2.33e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—IL6—lung cancer	4.46e-06	2.33e-05	CbGpPWpGaD
Mesalazine—CHUK—Immune System—AKT1—lung cancer	4.46e-06	2.33e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—IL6—lung cancer	4.38e-06	2.29e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—EP300—lung cancer	4.32e-06	2.26e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MAPK3—lung cancer	4.27e-06	2.23e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—EP300—lung cancer	4.26e-06	2.22e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—CDKN1A—lung cancer	4.24e-06	2.22e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PTEN—lung cancer	4.23e-06	2.21e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—SRC—lung cancer	4.2e-06	2.2e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—MYC—lung cancer	4.16e-06	2.17e-05	CbGpPWpGaD
Mesalazine—CHUK—Disease—AKT1—lung cancer	4.12e-06	2.15e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PIK3CB—lung cancer	4.1e-06	2.14e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—VEGFA—lung cancer	4.1e-06	2.14e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—EGFR—lung cancer	4.06e-06	2.12e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—STAT3—lung cancer	4.06e-06	2.12e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—NRAS—lung cancer	4.05e-06	2.11e-05	CbGpPWpGaD
Mesalazine—IKBKB—Immune System—AKT1—lung cancer	4.04e-06	2.11e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—EP300—lung cancer	4.03e-06	2.11e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—SRC—lung cancer	3.92e-06	2.05e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MAPK3—lung cancer	3.87e-06	2.03e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—KRAS—lung cancer	3.84e-06	2.01e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—STAT3—lung cancer	3.78e-06	1.98e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—NRAS—lung cancer	3.77e-06	1.97e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—MYC—lung cancer	3.77e-06	1.97e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—EGFR—lung cancer	3.69e-06	1.93e-05	CbGpPWpGaD
Mesalazine—PPARG—Metabolism—AKT1—lung cancer	3.67e-06	1.92e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—MAPK3—lung cancer	3.61e-06	1.89e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PTEN—lung cancer	3.54e-06	1.85e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—PIK3CA—lung cancer	3.53e-06	1.84e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—MYC—lung cancer	3.52e-06	1.84e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—KRAS—lung cancer	3.48e-06	1.82e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—EGFR—lung cancer	3.44e-06	1.8e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—TP53—lung cancer	3.41e-06	1.78e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—EP300—lung cancer	3.38e-06	1.77e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—HRAS—lung cancer	3.26e-06	1.71e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—KRAS—lung cancer	3.25e-06	1.7e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—PIK3CA—lung cancer	3.2e-06	1.67e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—PIK3CA—lung cancer	3.15e-06	1.65e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—IL6—lung cancer	3.12e-06	1.63e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—TP53—lung cancer	3.09e-06	1.62e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—PIK3CA—lung cancer	2.98e-06	1.56e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—HRAS—lung cancer	2.96e-06	1.55e-05	CbGpPWpGaD
Mesalazine—CHUK—Signaling Pathways—AKT1—lung cancer	2.88e-06	1.51e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—IL6—lung cancer	2.83e-06	1.48e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—HRAS—lung cancer	2.76e-06	1.44e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—IL6—lung cancer	2.64e-06	1.38e-05	CbGpPWpGaD
Mesalazine—IKBKB—Signaling Pathways—AKT1—lung cancer	2.61e-06	1.37e-05	CbGpPWpGaD
Mesalazine—PTGS1—Metabolism—AKT1—lung cancer	2.57e-06	1.34e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—PIK3CA—lung cancer	2.5e-06	1.31e-05	CbGpPWpGaD
Mesalazine—PTGS2—Disease—AKT1—lung cancer	2.44e-06	1.27e-05	CbGpPWpGaD
Mesalazine—PTGS2—Metabolism—AKT1—lung cancer	2.04e-06	1.07e-05	CbGpPWpGaD
